Current status of intensity-modulated radiation therapy (IMRT)

Hatano, Kazuo; Araki, Hitoshi; Sakai, Mitsuhiro; Kodama, Takashi; Tohyama, Naoki; Kawachi, Toru; Imazeki, Masaharu; Shioiri, Takayuki; Iwase, Takushi; Shinozuka, Minoru; Ishigaki, Hideyo

doi:10.1007/s10147-007-0703-9

Cited by 22 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar studies have found that the mean tumor doses treated with 131 I-tositumomab are 3 Gy [6] and 3.7 Gy in previously untreated patients [7]. In comparison, high doses of standard radiation therapy are needed to achieve clinical responses in solid tumors such as prostate cancer (64.8–81 Gy) [8], lung cancer (40–65 Gy) [9], glioma (60 Gy) [10], breast cancer (50 Gy) [11], ovarian cancer (45 Gy) [5], colorectal cancer (70 Gy) [12] and pancreatic cancer (50.4 Gy) [13]. Based on these clinical experiences, it is generally accepted that solid tumor doses need to reach at least 50 Gy to achieve any clinical benefits.…”

Section: Introductionmentioning

confidence: 93%

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

Song

Sgouros²

2011

CDD

View full text Add to dashboard Cite

Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkin’s lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under pre-clinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.

show abstract

Section: Introductionmentioning

confidence: 93%

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

Song

Sgouros²

2011

CDD

View full text Add to dashboard Cite

show abstract

“…One publication states ''even with IMRT, . a ''perfect'' plan that creates completely homogeneous coverage of the target volume and zero or small dose to the adjacent organs at risk is not always obtained'' (16). Indeed, it is impossible to achieve such a ''perfect'' plan.…”

Section: Understanding the Clinical Utility Of Our Processesmentioning

confidence: 98%

The Need for Physician Leadership in Creating a Culture of Safety

Marks

Rose²,

Hayman

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Such reviews can be found in recent books 62,63 and review articles. [64][65][66][67] We attempt to predict from what we learned in the last 10 years of development and clinical practice of IMRT the potential direction of further advancement in the near future. IMRT technology consists of planning methods and delivery technologies.…”

Section: Overviewmentioning

confidence: 99%

Planning and delivery of intensity‐modulated radiation therapy

Amies²,

Svatos

2008

Medical Physics

View full text Add to dashboard Cite

Intensity modulated radiation therapy (IMRT) is an advanced form of external beam radiation therapy. IMRT offers an additional dimension of freedom as compared with field shaping in three-dimensional conformal radiation therapy because the radiation intensities within a radiation field can be varied according to the preferences of locations within a given beam direction from which the radiation is directed to the tumor. This added freedom allows the treatment planning system to better shape the radiation doses to conform to the target volume while sparing surrounding normal structures. The resulting dosimetric advantage has shown to translate into clinical advantages of improving local and regional tumor control. It also offers a valuable mechanism for dose escalation to tumors while simultaneously reducing radiation toxicities to the surrounding normal tissue and sensitive structures. In less than a decade, IMRT has become common practice in radiation oncology. Looking forward, the authors wonder if IMRT has matured to such a point that the room for further improvement has diminished and so it is pertinent to ask what the future will hold for IMRT. This article attempts to look from the perspective of the current state of the technology to predict the immediate trends and the future directions. This article will (1) review the clinical experience of IMRT; (2) review what we learned in IMRT planning; (3) review different treatment delivery techniques; and finally, (4) predict the areas of advancements in the years to come.

show abstract

Current status of intensity-modulated radiation therapy (IMRT)

Cited by 22 publications

References 44 publications

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

The Need for Physician Leadership in Creating a Culture of Safety

Planning and delivery of intensity‐modulated radiation therapy

Contact Info

Product

Resources

About